- Home
- FBIOP vs SCLXW Comparison
FBIOP vs SCLXW Comparison
Compare FBIOP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- SCLXW
- Stock Information
- Founded
- FBIOP N/A
- SCLXW N/A
- Country
- FBIOP United States
- SCLXW United States
- Employees
- FBIOP 101
- SCLXW 31
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- FBIOP Health Care
- SCLXW Health Care
- Exchange
- FBIOP Nasdaq
- SCLXW Nasdaq
- Market Cap
- FBIOP N/A
- SCLXW N/A
- IPO Year
- FBIOP N/A
- SCLXW N/A
- Fundamental
- Price
- FBIOP $6.82
- SCLXW $0.16
- Analyst Decision
- FBIOP
- SCLXW
- Analyst Count
- FBIOP 0
- SCLXW 0
- Target Price
- FBIOP N/A
- SCLXW N/A
- AVG Volume (30 Days)
- FBIOP N/A
- SCLXW 4.0K
- Earning Date
- FBIOP N/A
- SCLXW 03-07-2025
- Dividend Yield
- FBIOP N/A
- SCLXW N/A
- EPS Growth
- FBIOP N/A
- SCLXW N/A
- EPS
- FBIOP N/A
- SCLXW N/A
- Revenue
- FBIOP N/A
- SCLXW $55,152,000.00
- Revenue This Year
- FBIOP N/A
- SCLXW N/A
- Revenue Next Year
- FBIOP N/A
- SCLXW N/A
- P/E Ratio
- FBIOP N/A
- SCLXW N/A
- Revenue Growth
- FBIOP N/A
- SCLXW 22.02
- 52 Week Low
- FBIOP N/A
- SCLXW $0.18
- 52 Week High
- FBIOP N/A
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- FBIOP 31.48
- SCLXW 41.02
- Support Level
- FBIOP $6.71
- SCLXW $0.11
- Resistance Level
- FBIOP $7.07
- SCLXW $0.13
- Average True Range (ATR)
- FBIOP 0.34
- SCLXW 0.03
- MACD
- FBIOP -0.10
- SCLXW 0.01
- Stochastic Oscillator
- FBIOP 16.95
- SCLXW 40.15
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.